These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10675148)

  • 1. Prophylaxis against respiratory syncytial virus in premature infants.
    Björklund LJ; Lindroth M; Polberger S; Selander B
    Lancet; 2000 Jan; 355(9199):235-6. PubMed ID: 10675148
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
    Top FH; Connor EM; Carlin DA
    Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylaxis for respiratory syncytial virus bronchiolitis.
    Nadal D; Berger C; Aebi C; Kind C
    Lancet; 1999 Dec; 354(9194):1997. PubMed ID: 10622321
    [No Abstract]   [Full Text] [Related]  

  • 4. Comments on palivizumab (Synagis).
    Moler FW; Brown RW; Faix RG; Gilsdorf JR
    Pediatrics; 1999 Feb; 103(2):495-7. PubMed ID: 9925848
    [No Abstract]   [Full Text] [Related]  

  • 5. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody against RSV helps prevent wheeze in infants.
    BMJ; 2013 May; 346():f3089. PubMed ID: 23678095
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.
    Greenough A
    Evid Based Med; 2014 Apr; 19(2):65. PubMed ID: 24142143
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K; Jung E; Fernández P; Zhao L; Harris B; Connor EM; Losonsky GA;
    Pediatr Infect Dis J; 2009 Apr; 28(4):267-72. PubMed ID: 19258920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for immunologic prevention of respiratory syncytial virus (RSV) infections].
    Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():16. PubMed ID: 10612193
    [No Abstract]   [Full Text] [Related]  

  • 13. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
    Korppi M
    Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
    Meissner HC; Welliver RC; Chartrand SA; Law BJ; Weisman LE; Dorkin HL; Rodriguez WJ
    Pediatr Infect Dis J; 1999 Mar; 18(3):223-31. PubMed ID: 10093942
    [No Abstract]   [Full Text] [Related]  

  • 15. Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
    Hampp C; Kauf TL; Winterstein AG
    Value Health; 2010 Aug; 13(5):684. PubMed ID: 20412545
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 18. Palivizumab use in very premature infants in the neonatal intensive care unit.
    Wu SY; Bonaparte J; Pyati S
    Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of respiratory syncytial viral infections in late preterm infants.
    Sankaran K; Kalappurackal M; Tan B
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Apr; 15(4):241-8. PubMed ID: 23607943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do.
    Manzoni P; Sala U; Gomirato G; Coscia A; Fabris C
    Pediatrics; 2005 May; 115(5):1439-40; author reply 1440-1. PubMed ID: 15867062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.